Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital160 AstraZeneca154 Janssen Research & Development, LLC58 Eli Lilly and Company45 Hoffmann-La Roche43
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Chengdu

1307 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 2
72
Chengdu
2025-08-08
Active, closed
AstraZeneca
Phase 3
212
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
China National Center for Cardiovascular Diseases
Early Phase 1
3,160
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu
2025-08-05
Recruiting
AbbVie
Phase 2/3
854
Beijing, Fuzhou, Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-08-03
Not yet open
Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui Da and Medtronic) in Radiofrequency Ablation for Varicose Veins
NCT07046286Varicose Veins of Lower Limb, Venous Insufficiency of Leg, Vascular Disease，Peripheral
Chengdu University of Traditional Chinese Medicine
Not applicable
200
Chengdu
2025-08-01
Recruiting
SightGlass Vision, Inc.
Not applicable
175
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2025-08-01
Recruiting
Sichuan University
Phase 1/2
40
Chengdu
2025-08-01
Recruiting
West China Hospital
Phase 1
15
Chengdu
2025-08-01
Recruiting
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Active, closed
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Recruiting
West China Hospital
Phase 1
15
Chengdu
2025-07-31
Not yet open
Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
NCT07088744Gastric Cancer (Diagnosis), Gastric High-grade Intraepithelial Neoplasia, Gastric Low-grade Intraepithelial Neoplasia, Gastritis
Changhai Hospital
Observational
169
Nanning, Shenyang, Chengdu, Shanghai
2025-07-30
Not yet open
West China Hospital
Not applicable
242
Chengdu
2025-07-30
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
Chengdu, Shanghai, Wuhan
2025-07-28
Recruiting
Cytocraft Biopharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-07-26
Recruiting
West China Hospital
Not applicable
5
Chengdu
2025-07-25
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
236
Beijin, Zhengzhou, Jinan, Chengdu, Shijia Zhuang
2025-07-24
Recruiting
West China Hospital
Not applicable
40
Chengdu
2025-07-23
Not yet open
Ke Dou
Not applicable
284
Chengdu
2025-07-22
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Not yet open
West China Hospital
Not applicable
20
Chengdu
2025-07-20
Recruiting
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3
390
Chengdu
2025-07-18
Recruiting
Sichuan University
Early Phase 1
10
Chengdu
2025-07-18
Recruiting
AstraZeneca
Phase 2
100
Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao
2025-07-17
Recruiting
West China Hospital
Not applicable
30
Chengdu
2025-07-15
Active, closed
Aligos Therapeutics
Phase 2
200
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai
2025-07-15
Recruiting
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
The Third Affiliated Hospital of Guangzhou Medical University
Not applicable
600
Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing
2025-07-12
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
210
Chongqing, Chengdu
2025-07-11
Recruiting
West China Hospital
Observational
300
Chengdu
2025-07-10
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
NCT07070323T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2025-07-09
Recruiting
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Not yet open
Sichuan Provincial People's Hospital
Not applicable
30
Chengdu
2025-07-07
Active, closed
West China Hospital
Phase 1/2
20
Chengdu
2025-07-07
Recruiting
Sichuan University
Phase 2
30
Chengdu
2025-07-04
Active, closed
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou
2025-07-02
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Not yet open
Sichuan Cancer Hospital and Research Institute
Not applicable
600
Chengdu
2025-07
Recruiting
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Active, closed
West China Hospital
Phase 2
70
Chengdu
2025-06-27
Active, closed
Incyte Corporation
Phase 1/2
32
Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan
2025-06-25
Active, closed
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Recruiting
Sichuan University
Phase 2
40
Chengdu
2025-06-25
Recruiting
West China Hospital
Phase 1/2
58
Chengdu
2025-06-25
Recruiting
A Study in Children With Achondroplasia
NCT07301463Achondroplasia
Abbisko Therapeutics Co, Ltd
Observational
260
Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou
2025-06-20
Recruiting
GlaxoSmithKline
Phase 3
981
Haikou, Changsha, Chengdu, Beijing, Changchun, Chongqing, Dongguan, Fuyang
2025-06-20
Recruiting
Huashan Hospital
Phase 2
80
Beijing, Chengdu, Shanghai
2025-06-18
Recruiting
West China Hospital
Observational
1,200
Chengdu
2025-06-16
Not yet open
Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia
NCT07007650Labor Analgesia, Prolonged, Ropivacaine, Concentration
Chengdu Jinjiang Maternity and Child Health Hospital
Not applicable
100
Chengdu
2025-06-14
Recruiting
FIH Study of PFLotus in Persistent Atrial Fibrillation
NCT07301190Persistent Atrial Fibrillation
The Third People's Hospital of Chengdu
Not applicable
40
Chengdu
2025-06-11
Recruiting
HighField Biopharmaceuticals Corporation
Early Phase 1
10
Chengdu
2025-06-11
Active, closed
West China Hospital
Phase 1/2
29
Chengdu
2025-06-10
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
University of Electronic Science and Technology of China
Early Phase 1
250
Chengdu
2025-06-09
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
DrugSGB-9768
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
Recruiting
Boehringer Ingelheim
Phase 2
300
Chengdu, Shanghai, Shenyang, Shijiazhuang, Taiyuan
2025-06-05
Recruiting
Sichuan University
Phase 1
20
Chengdu
2025-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Not yet open
Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery
NCT06763991Microtia, Outcome Assessment, RCT, Surgery Related Complications Rate
Sichuan Provincial People's Hospital
Not applicable
78
Chengdu
2025-06-01
Recruiting
Yuju Wu
Not applicable
320
Chengdu
2025-06-01
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, Ürümqi
2025-06-01
Recruiting
West China Second University Hospital
Phase 2
20
Chengdu
2025-06-01
Recruiting
Xijing Hospital
Observational
300
Wuwei, Shantou, Zhaoqing, Zhengzhou, Xi'an, Yan’an, Taiyuan, Chengdu
2025-05-26
Recruiting
Sichuan Provincial People's Hospital
Phase 3
5,138
Chengdu
2025-05-23
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
220
Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu
2025-05-20
Recruiting
The Hong Kong Polytechnic University
Not applicable
30
Chengdu
2025-05-20
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian
2025-05-20
Active, closed
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Active, closed
Amgen
Phase 1
29
Jinan, Chengdu, Fuzhou
2025-05-16
Active, closed
Eli Lilly and Company
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase 3
560
Cangzhou, Changde, Changsha, Chengdu, Chongqing, Ch’ang-ch’un, Dalian, Deyang
2025-05-14
Recruiting
Hoffmann-La Roche
Phase 3
425
Ganzhou, Jinhua, Beijing, Chengdu, Guangzhou, Haikou, Huai'an, Huizhou
2025-05-12
Recruiting
West China Hospital
Phase 1
12
Chengdu
2025-05-09
Recruiting
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Not yet open
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC
NCT06966583Solid Tumor, Non Small Cell Lung Cancer
Sichuan University
Phase 1
20
Chengdu
2025-05-01
Not yet open
West China Hospital
Not applicable
600
Chengdu
2025-05-01
Not yet open
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Not yet open
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
NCT06961201Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
DrugNano-crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
94
Chengdu
2025-05-01
Not yet open
A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations
NCT06840691Pediatric Growth Hormone Deficiency (PGHD)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
87
Chengdu
2025-05
Active, closed
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Beijing, Chengdu, Shanghai, Wuhan
2025-04-29
Recruiting
Xijing Hospital
Observational
450
Xi'an, Chengdu, Beijing, Shanghai
2025-04-24
Recruiting
BioNTech SE
Phase 1/2
380
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
2025-04-23
Recruiting
InnoVec Biotherapeutics Inc.
Phase 1
18
Chengdu
2025-04-22
Recruiting
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
NCT06878612Polyphenols, Cancer Vaccine, Advanced Solid Tumor
Xingchen Peng
Phase 1
9
Chengdu
2025-04-21
Recruiting
West China Hospital
Phase 2
23
Chengdu
2025-04-16
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
DrugSIRT
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xi’an, Chengdu
2025-04-15
Active, closed
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
NCT06866574Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
Xiamen University
Phase 3
9,300
Fuzhou, Chengdu, Kunming, Hangzhou
2025-04-11
Active, closed
Lu Jiang
Not applicable
60
Chengdu
2025-04-10
Recruiting
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
Epygenix
Phase 3
260
Changsha, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang
2025-04-09
Recruiting
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Recruiting
Huazhong University of Science and Technology
Not applicable
2,500
Nanning, Tangshan, Shiyan, Wuhan, Chengdu
2025-04-08
Recruiting
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
NCT06950814Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy
West China Hospital
Observational
50
Chengdu
2025-04-05
Recruiting
Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
NCT06950827Hepatocellular Carcinoma, Hepatectomy, Laparoscopic Hepatectomy
West China Hospital
Observational
400
Chengdu
2025-04-05
Recruiting
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
NCT06348797Small Cell Lung Cancer Extensive Stage
Sichuan University
Phase 1
30
Chengdu
2025-04-03
Recruiting
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
By invitation
Nanjing Medical University
Not applicable
200
Beijing, Guangzhou, Shanghai, Chengdu
2025-04-01
Recruiting
Pain Relief From Dysmenorrhea Employing taVNS
NCT06912386Dysmenorrhea Primary
University of Electronic Science and Technology of China
Not applicable
20
Chengdu
2025-04-01
Not yet open
Sichuan Provincial People's Hospital
Not applicable
20
Chengdu
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Not yet open
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
60
Chengdu
2025-04
Active, closed
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
436
Chengdu
2025-03-31
Recruiting
West China Hospital
Observational
459
Chengdu
2025-03-29
Recruiting
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
AstraZeneca
Phase 1/2
304
Chengdu, Guangzhou, Harbin, Shanghai
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Hangzhou, Harbin
2025-03-27
Recruiting
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Recruiting
Allogeneic UCB-derived CAR-T for SLE
NCT07274059SLE - Systemic Lupus Erythematosus
Chengdu Ucello Biotechnology Co., Ltd.
Early Phase 1
48
Yancheng, Chengdu
2025-03-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
iCell Gene Therapeutics
Phase 1
10
Chengdu
2025-03-20
Recruiting
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
Sichuan Provincial People's Hospital
Observational
50
Chengdu
2025-03-19
Recruiting
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Active, closed
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
West China Hospital
Phase 2
28
Chengdu
2025-03-15
Recruiting
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Active, closed
Hoffmann-La Roche
Phase 4
274
Beijing, Chengdu, Guangzhou, Shanghai, Wuhan
2025-03-14
Active, closed
Ruijin Hospital
Phase 1
9
Guangzhou, Shanghai, Chengdu
2025-03-12
Active, closed
Kylonova (Xiamen) Biopharma co., LTD.
Phase 1
50
Chengdu
2025-03-12
Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.
Phase 1
96
Fuzhou, Guangzhou, Shanghai, Chengdu
2025-03-06
Recruiting
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Recruiting
University of Electronic Science and Technology of China
Phase 1
70
Chengdu
2025-03-01
Not yet open
Sichuan Cancer Hospital and Research Institute
Phase 1/2
292
Chengdu
2025-03-01
Recruiting
West China Hospital
Phase 2
25
Chengdu
2025-03-01
Recruiting
Investigation of Tetralogy of Fallot in Neonates
NCT06822400Tetralogy of Fallot (TOF), Pulmonary Stenosis, Ventricular Septal Defects (VSD), Double Outlet Right Ventricle
Beijing Anzhen Hospital
Not applicable
160
Beijing, Chengdu, Shanghai, Shenzhen, Suzhou
2025-03-01
Recruiting
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
Visual Adaptation and Quality of Life After Different IOL Implantation Strategies
NCT07740590Cataract, Aphakia - Lens Capsule Present
Sichuan Academy of Medical Sciences
Observational
264
Chengdu
2025-03-01
Not yet open
Ahon Pharmaceutical Co., Ltd.
Phase 3
270
Beijing, Shenzhen, Chengdu, Guangyuan, Yibin
2025-03
Recruiting
Sichuan University
Not applicable
180
Chengdu
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Beijing, Lanzhou, Wuhan, Yantai, Chengdu, Kunming
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL
NCT06763055Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage, Supratentorial Intracerebral Haemorrhage, Acute Intracerebral Haemorrhage
DrugColchicine
The George Institute
Phase 3
2,000
Chengdu
2025-02-27
Active, closed
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Active, closed
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
NCT06865521Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
West China Hospital
Not applicable
22
Chengdu
2025-02-21
By invitation
The Third People's Hospital of Chengdu
Observational
12,000
Chengdu
2025-02-20
Recruiting
IBSA Farmaceutici Italia Srl
Not applicable
500
Beijing, Changde, Chengdu, Shanghai, Xi'an
2025-02-19
Active, closed
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Active, closed
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy
NCT06819748Cholecystectomy, Laparoscopic, Ambulatory Surgical Procedures, Multimodal Analgesia
DrugRopivacaine
Sichuan Provincial People's Hospital
Not applicable
210
Chengdu
2025-02-14
Active, closed
ExoRNA Bioscience
Phase 1/2
27
Guangzhou, Chengdu
2025-02-11
Active, closed
West China Hospital
Phase 1/2
20
Chengdu
2025-02-10
Recruiting
Fan Zeng
Not applicable
296
Chengdu
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Chifeng, Suzhou, Beijing, Chengdu, Fujian
2025-02-10
Active, closed
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
Recruiting
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
By invitation
Development and Verification of a Screening Tool for Comprehensive Geriatric Assessment of Elderly Tumor Patients
NCT06761534Geriatric Assessment, Geriatric Patients, Patients With Cancer, Assessment Tool
Sichuan Cancer Hospital and Research Institute
Observational
678
Chengdu
2025-02-05
Recruiting
Sichuan University
Phase 2
80
Chengdu
2025-02-01
Recruiting
Sichuan University
Phase 2
28
Chengdu
2025-02-01
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
NCT07872423Anti IL-6R, Castleman's Disease, Multicentric
Beijing VDJBio Co., LTD.
Phase 3
45
Beijing, Xiamen, Wuhan, Nanjing, Nanchang, Taiyuan, Chengdu, Hangzhou
2025-01-27
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
240
Chengdu
2025-01-22
Not yet open
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
Weiwei Zhang
Phase 2
35
Chengdu
2025-01-20
Recruiting
Xingchen Peng
Phase 1
6
Chengdu
2025-01-20
Recruiting
The Eye Hospital of Wenzhou Medical University
Observational
1,000,000
Guangzhou, Chengdu, Wenzhou
2025-01-19
Active, closed
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2
320
Chengdu
2025-01-17
Recruiting
Shanghai Auzone Biological Technology Co., Ltd.
Phase 2
150
Beijing, Changsha, Chengdu, Nanjing, Tianjin
2025-01-13
Recruiting
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
NCT07748325Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
DrugSintilimab
Sichuan University
Phase 2
100
Chengdu, Suining
2025-01-10
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Active, closed
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Ha’erbin, Hefei, Jiangmen, Kunming
2025-01-09
Recruiting
Peking University First Hospital
Phase 4
84
Changsha, Jinan, Chengdu, Ürümqi, Wenzhou, Beijing, Shanghai
2025-01-07
Not yet open
Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.
NCT06772428Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors
DrugNano-crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
96
Chengdu
2025-01-01
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
358
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2025-01-01
Recruiting
Gang Wang
Not applicable
214
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jining, Chengdu, Tianjin, Dali
2025-01-01
By invitation
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu, Shanghai
2025-01-01
Recruiting
West China Hospital
Phase 2/3
32
Chengdu
2025-01-01
Not yet open
West China Hospital
Phase 2
50
Chengdu
2025-01-01
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Not yet open
Erector Spinae Plane Block v.s Patient Controlled Analgesia in Correction Surgery for Idiopathic Scoliosis
NCT06728046Idiopathic Scoliosis, Erector Spinae Plane Block, Patient Controlled Analgesia
West China Hospital
Not applicable
40
Chengdu
2025-01-01
Not yet open
Fascia Iliaca Compartment Block and Tramadol for Analgesia in Hip Fracture
NCT06728033Hip Fractures, Ultrasound-guided Nerve Block, Perioperative Analgesia
DrugTramadol
West China Hospital
Not applicable
240
Chengdu
2025-01-01
Not yet open
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Recruiting
West China Hospital
Phase 1/2
57
Chengdu
2024-12-31
Not yet open
Tasly Pharmaceutical Group Co., Ltd
Phase 3
520
Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng
2024-12-30
Active, closed
Suzhou HepaThera Biotech Co., Ltd.
Phase 1/2
86
Beijing, Xiamen, Guangzhou, Qingyuan, Shanghai, Chengdu
2024-12-30
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 3
63
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2024-12-27
Recruiting
Jie Li
Not applicable
200
Chengdu
2024-12-26
Recruiting
Ractigen Therapeutics.
Phase 1
32
Beijing, Chengdu, Hangzhou
2024-12-24
Recruiting
Xingchen Peng
Phase 1/2
158
Chengdu
2024-12-22
Recruiting
HAPA-based Intervention in Adults With Metabolic Syndrome and Chronic Kidney Disease
NCT06715735Chronic Kidney Diseases, Metabolic Syndrome
Chinese University of Hong Kong
Not applicable
160
Chengdu
2024-12-20
Recruiting
Sanofi
Phase 2
84
Beijing, Chengdu, Shanghai
2024-12-19
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
90
Chengdu
2024-12-18
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1
206
Nanjing, Chengdu
2024-12-17
Recruiting
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
142
Xiamen, Wuhan, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Linyi
2024-12-12
Recruiting
GlaxoSmithKline
Phase 3
514
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
2024-12-12
Recruiting
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanning
2024-12-11
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xi’an, Chengdu
2024-12-09
Active, closed
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Recruiting
Observation of Pain During the Treatment of Great Saphenous Vein Using Microwave Ablation， and Analysis of Related Factors
NCT06693245Vascular Disease，Peripheral, Venous Insufficiency of Leg, Varicose Veins of Lower Limb
Chengdu University of Traditional Chinese Medicine
Observational
155
Chengdu
2024-12-01
Recruiting
Comparative Analysis of Radiofrequency Ablation and Microwave Ablation Procedures for the Treatment of Small Saphenous Varicose Veins
NCT06711120Varicose Veins of Lower Limb, Venous Insufficiency of Leg, Vascular Disease，Peripheral
Chengdu University of Traditional Chinese Medicine
Not applicable
150
Chengdu
2024-12-01
Not yet open
West China Hospital
Phase 2
20
Chengdu
2024-12-01
Recruiting
The General Hospital of Western Theater Command
Early Phase 1
30
Chengdu
2024-12-01
Recruiting
West China Hospital
Phase 2/3
150
Chengdu
2024-11-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
136
Shanghai, Chengdu
2024-11-28
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Active, closed
Ruijin Hospital
Phase 2
80
Chengdu, Shanghai, Yantai
2024-11-21
Active, closed
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 3
401
Chengdu
2024-11-21
Recruiting
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
NCT07020247Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
West China Hospital
Phase 3
184
Chengdu
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Recruiting
Sichuan Cancer Hospital and Research Institute
Not applicable
148
Chengdu
2024-11-18
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
162
Chengdu
2024-11-13
Recruiting
Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices
NCT06652750Sick Sinus Syndrome, Atrioventricular Block, Second and Third Degree, Heart Failure
The Third People's Hospital of Chengdu
Not applicable
688
Guangzhou, Chengdu
2024-11-13
Active, closed
Biotheus Inc.
Phase 3
404
Binzhou, Changchun, Changsha, Chengdu, Chenzhou, Chongqing, Dalian, Foshan
2024-11-13
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-11-12
Active, closed
GlaxoSmithKline
Phase 2
283
Beijing, Chengdu, Guangzhou, Shanghai
2024-11-11
Recruiting
West China Hospital
Observational
10,000
Chengdu
2024-11-11
Not yet open
West China Hospital
Not applicable
150
Nanchang, Chengdu
2024-11-10
Recruiting
West China Hospital
Phase 3
100
Chengdu
2024-11-10
Active, closed
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Active, closed
The Third People's Hospital of Chengdu
Not applicable
34
Chengdu
2024-11-06
By invitation
Minimal Vitrectomy and ILM Flap with Sodium Hyaluronate Gel for MH
NCT06685328Macular Hole, Macular Hole Surgery, Idiopathic Macular Hole, Macular Hole of Left Eye (Disorder)
Jie Zhong
Not applicable
52
Chengdu
2024-11-01
Recruiting
West China Hospital
Phase 3
186
Chengdu
2024-11-01
Recruiting
Brii Biosciences Limited
Phase 2
250
Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-10-31
Recruiting
Akeso
Phase 3
510
Wuhan, Chengdu
2024-10-30
Recruiting
Sichuan Provincial People's Hospital
Observational
200
Chengdu
2024-10-30
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
432
Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou
2024-10-30
Active, closed
West China Hospital
Phase 1
6
Chengdu
2024-10-27
Active, closed
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Active, closed
Servier
Phase 3
57
Shenzhen, Chengdu, Beijing, Shanghai, Xi'an
2024-10-18
Active, closed
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Not yet open
Peking University Third Hospital
Early Phase 1
7
Beijing, Fujian, Nanjing, Chengdu, Hangzhou
2024-10-16
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-10-14
Active, closed
3-Dimensional Mapping System: The PULSTAR II Study
NCT07586176Atrial Fibrillation (Paroxysmal), Paroxysmal AF, Pulsed Field Ablation
Shanghai Shangyang Medical Technology Co., Ltd.
Not applicable
152
Chengdu
2024-10-10
Active, closed
West China Hospital
Phase 2
58
Chengdu
2024-10-10
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nanning, Zhengzhou, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
By invitation
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2024-10-08
Active, closed
AstraZeneca
Phase 3
768
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Deyang, Ganzhou
2024-10-04
Recruiting
West China Hospital
Phase 2
36
Chengdu
2024-10-01
Recruiting
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
NCT06675201Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
Sichuan University
Phase 2
165
Chengdu
2024-10-01
Not yet open
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
NCT06666153CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs
West China Hospital
Phase 1
27
Chengdu
2024-10
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Not yet open
Meng Qiu
Phase 3
452
Chengdu
2024-09-26
Active, closed
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-09-26
Active, closed
AstraZeneca
Phase 3
293
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang
2024-09-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Beijing, Chengdu, Shanghai
2024-09-19
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Active, closed
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
By invitation
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
NCT06504043Hypercholesterolemia, Healthy Volunteers, LDL-Cholesterol
DrugLerodalcibep
Hasten Biopharmaceutical Co., Ltd.
Phase 1
30
Chengdu
2024-09-17
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Recruiting
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Recruiting
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Hangzhou Valgen Medtech Co., Ltd
Not applicable
236
Chengdu, Hangzhou
2024-09-03
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
By invitation
Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease
NCT06641843Kawasaki Disease, Cardiovascular Disease, Anomalous Origin of Coronary Artery
West China Second University Hospital
Observational
240
Chengdu
2024-09-01
By invitation
West China Second University Hospital
Observational
800
Chengdu
2024-09-01
Recruiting
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Recruiting
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
AI App for Management of Atopic Dermatitis
NCT06362629Atopic Dermatitis, Artificial Intelligence
West China Hospital
Not applicable
232
Chengdu
2024-09-01
Recruiting
iCell Gene Therapeutics
Phase 1
20
Chengdu
2024-08-31
Recruiting
West China Hospital
Phase 2
51
Chengdu
2024-08-30
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Active, closed
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Recruiting
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Jiazhuang, Jinan, Nanchang
2024-08-21
Active, closed
AbbVie
Phase 3
699
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
Recruiting
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
80
Beijing, Fuzhou, Wenzhou, Changsha, Nanjing, Suzhou, Qingdao, Chengdu
2024-08-16
Recruiting
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Recruiting
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
NCT06485466Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
Guohui Xu
Phase 3
101
Chengdu
2024-08-10
Recruiting
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
138
Chengdu
2024-08-07
Recruiting
A Study of Online Follow-up in Patients With Papillary Thyroid Cancer
NCT06800482Thyroid, Papillary Thyroid Cancer
West China Hospital
Not applicable
388
Chengdu
2024-08-07
Recruiting
West China Hospital
Not applicable
16
Chengdu, Zigong
2024-08-03
Recruiting
West China Hospital
Not applicable
12
Chengdu
2024-08-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Recruiting
Sichuan Cancer Hospital and Research Institute
Phase 2
20
Chengdu
2024-08-01
Recruiting
Zhengzhou Children's Hospital, China
Not applicable
90
Chengdu, Liangshan, Zhengzhou, Ziyang
2024-07-31
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Recruiting
Chinese University of Hong Kong
Not applicable
40
Chengdu
2024-07-31
Active, closed
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 3
6,600
Nanning, Changsha, Chengdu
2024-07-27
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugAdebrelimab
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
West China Hospital
Phase 1
6
Chengdu
2024-07-22
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
200
Chengdu
2024-07-19
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Recruiting
West China Second University Hospital
Not applicable
90
Chengdu
2024-07-17
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
Johnson & Johnson Medical (Shanghai) Ltd.
Observational
6,111
Chengdu, Kunming, Shenzhen
2024-07-14
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Active, closed
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3
9,000
Nanning, Changsha, Taiyuan, Chengdu, Kunming
2024-07-11
Active, closed
FIH of PFBalloon for PVI
NCT07320976Paroxysmal Atrial Fibrillation
The Third People's Hospital of Chengdu
Not applicable
35
Chengdu
2024-07-10
Recruiting
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Guangzhou, Zhengzhou, Wuhan, Changsha, Shang'ai, Shanghai, Chengdu, Hangzhou
2024-07-09
Recruiting
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT07923214Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Phase 1
30
Fuzhou, Dalian, Shanghai, Chengdu
2024-07-02
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Recruiting
Lei Liu
Phase 2
90
Chengdu
2024-07-01
Recruiting
Peking University People's Hospital
Observational
30
Beijing, Chengdu, Guangdong, Kunming, Nanjing, Nanning, Nanyang, Ningbo
2024-07-01
Recruiting
Sichuan University
Phase 2
30
Chengdu
2024-06-30
Recruiting
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Active, closed
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Early Phase 1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2024-06-18
Recruiting
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Active, closed
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian
2024-06-17
Recruiting
Sichuan Provincial People's Hospital
Not applicable
200
Chengdu
2024-06-15
Recruiting
Chunling Jiang
Observational
200
Chengdu
2024-06-15
Recruiting
RemeGen Co., Ltd.
Phase 1/2
24
Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin
2024-06-14
Active, closed
GlaxoSmithKline
Phase 3
88
Chengdu, Hangzhou, Hefei, Nanjing, Shanghai
2024-06-10
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Recruiting
AstraZeneca
Observational
850
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai
2024-06-05
Recruiting
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Active, closed
West China Hospital
Observational
850,000
Chengdu
2024-06-01
Recruiting
Individualized ANH for Non-cardiac Surgery
NCT06399536Transfusion Related Complication, Hemodilution
West China Hospital
Not applicable
40
Chengdu
2024-06-01
Recruiting
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
103
Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai
2024-05-30
Recruiting
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Recruiting
A Clinical Study of SPH7854 Granules in Healthy Subjects.
NCT06483373Inflammatory Bowel Disease
Shanghai Pharmaceuticals Holding Co., Ltd
Early Phase 1
111
Chengdu
2024-05-28
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Active, closed
Sichuan University
Phase 1/2
57
Chengdu
2024-05-16
Recruiting
Wen Tianfu
Phase 3
196
Chengdu
2024-05-10
Recruiting
Sichuan Provincial People's Hospital
Observational
280
Chengdu
2024-05-10
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
132
Guanzhou, Chengdu
2024-05-08
Active, closed
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Active, closed
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
75
Chengdu, Tianjin
2024-05-06
Recruiting
West China Hospital
Not applicable
524
Chengdu
2024-05-06
Not yet open
Sichuan University
Phase 1
20
Chengdu
2024-05-01
Recruiting
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
NCT06361589ALK-positive Non-small Cell Lung Cancer, Real World Study
DrugLorlatinib
Sichuan Cancer Hospital and Research Institute
Observational
200
Chengdu
2024-05-01
Recruiting
Sichuan University
Not applicable
120
Chengdu
2024-05-01
Active, closed
A Machine Learning-based Estimated Survival Model
NCT06432283Advanced Solid Tumor
Zhao Siyao
Observational
1,000
Chengdu
2024-05-01
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
NeuShen Therapeutics
Phase 1
76
Chengdu
2024-04-30
Recruiting
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
510
Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou
2024-04-29
Recruiting
CSL Behring
Phase 2/3
3,110
Baotou Shi, Beijeing, Beijing, Chengdu, Dalian, Deyang Shi, Dongguan, Foshan Shi
2024-04-27
Recruiting
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
NCT06431685NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
DrugsSintilimab·Pemetrexed
Sichuan University
Phase 1
10
Chengdu
2024-04-25
Active, closed
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Recruiting
Sichuan University
Phase 1
24
Chengdu
2024-04-18
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2024-04-18
Recruiting
Sichuan University
Phase 1/2
45
Chengdu
2024-04-18
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot
2024-04-16
Active, closed
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
NCT06485219Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
DrugPurinostat Mesylate
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
50
Shanghai, Chengdu
2024-04-14
Recruiting
AstraZeneca
Phase 3
3,850
Baotou, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Guangzhou
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Recruiting
Eye & ENT Hospital of Fudan University
Observational
180
Beijing, Zhengzhou, Changsha, Nanchang, Shanghai, Chengdu
2024-04-06
Recruiting
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
NCT06326021Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital
Phase 1
27
Shanghai, Chengdu, Beijing
2024-04-02
Recruiting
Sichuan University
Phase 1
43
Chengdu
2024-04-01
Recruiting
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
NCT06308328Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
Nanfang Hospital, Southern Medical University
Observational
718
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Shanghai, Chengdu
2024-04-01
Recruiting
Sichuan Cancer Hospital and Research Institute
Not applicable
20
Chengdu
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Active, closed
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc
Phase 2
282
Changsha, Nanjing, Jining, Chengdu, Beijing, Chongqing
2024-03-28
Active, closed
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
260
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
144
Chengdu
2024-03-25
Recruiting
West China Hospital
Phase 2
60
Guiyang, Chengde, Chengdu, Kunming
2024-03-25
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
80
Beijing, Shanghai, Chengdu
2024-03-22
Recruiting
GlaxoSmithKline
Phase 3
864
Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan
2024-03-21
Active, closed
Intuitive Surgical
Not applicable
354
Shanghai, Chengdu
2024-03-20
Recruiting
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
NCT06398977Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors
DrugDapagliflozin
Sichuan Academy of Medical Sciences
Not applicable
70
Chengdu
2024-03-11
Recruiting
Chengdu FenDi Pharmaceutical Co., Ltd.
Phase 1
72
Chengdu
2024-03-11
Active, closed
Eli Lilly and Company
Phase 3
17,300
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng, Chongqing
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Recruiting
Sichuan University
Phase 2
114
Chongqing, Guiyang, Wuhan, Chengdu, Nanchong
2024-03-01
Recruiting
Sichuan University
Phase 1/2
40
Chengdu
2024-02-29
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Chengdu, Guangzhou
2024-02-26
Recruiting
Study of Natural Course Progression of Diabetic Retinopathy
NCT06269419Biomarkers of Diabetic Retinopathy
Jie Li
Observational
200
Chengdu
2024-02-25
Active, closed
AstraZeneca
Phase 2
127
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou
2024-02-22
Recruiting
AstraZeneca
Phase 3
5,250
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng
2024-02-21
Active, closed
AbbVie
Observational
1,200
Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua
2024-02-19
Recruiting
The General Hospital of Western Theater Command
Phase 1/2
200
Chengdu
2024-02-18
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Active, closed
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Recruiting
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
257
Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu
2024-02-04
Active, closed
West China Hospital
Phase 1
3
Chengdu
2024-01-31
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Active, closed
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
33
Nanjing, Chengdu, Ningbo
2024-01-19
Recruiting
AstraZeneca
Phase 1/2
334
Beijing, Chengdu, Shanghai, Wuhan
2024-01-18
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-01-11
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Active, closed
AbbVie
Phase 4
120
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Wuhan, Qingdao, Chengdu
2024-01-09
Recruiting
AstraZeneca
Observational
355
Chengdu, Beijing, Changsha, Dongguan, Foshan, Guangzhou, Hainan, Hohhot
2024-01-08
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Beijing, Changsha, Chengdu, Nanchang, Qingdao, Shanghai, Shenzhen
2024-01-03
Recruiting
Neuromodulation and Attention Deficits in MDD
NCT07111169Major Depression Disorder, Cognitive Deficits, Selective Attention
University of Electronic Science and Technology of China
Not applicable
60
Chengdu
2024-01-01
By invitation
18F-MFBG Cardiac Imaging for Heart Failure Administration
NCT06149195Rest Gated Myocardial Perfusion Imaging in Heart Failure
Sichuan Provincial People's Hospital
Observational
100
Chengdu
2024-01-01
Recruiting
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
Sichuan University
Phase 1
29
Chengdu
2024-01-01
Recruiting
First Hospital of China Medical University
Observational
600
Fuzhou, Dalian, Shenyang, Chengdu
2024-01-01
Not yet open
Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis
NCT06122753Portal Hypertension, Portal Vein Thrombosis, Esophageal Varix Bleeding, Portosystemic Shunt
West China Hospital
Not applicable
120
Chengdu
2024-01
Recruiting
Juan LI, MD
Phase 2
20
Chengdu
2023-12-31
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
NCT06189495Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
DrugGenSci048
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
30
Beijing, Wuhan, Jinan, Chengdu
2023-12-30
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Active, closed
Sanofi
Phase 3
943
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang
2023-12-27
Recruiting
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Active, closed
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
AstraZeneca
Phase 3
1,145
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Changsha, Chengdu
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
West China Hospital
Not applicable
100
Chengdu
2023-12-10
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi
2023-12-07
Recruiting
Emotion Regulation Dysfunctions in NSSI Adolescents in Naturalistic Contexts
NCT05907421Nonsuicidal Self Injury, Emotion Regulation
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Recruiting
Social Feedback and Dysfunctional Risk Taking in NSSI Adolescents
NCT05981677Nonsuicidal Self Injury, Risk-Taking
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Recruiting
Impact of Emotional Reactivity on Dysfunctional Decision-Making in NSSI Adolescents
NCT05981612Nonsuicidal Self Injury, Prediction Errors
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Recruiting
Altered Neural Pain Empathic Reactivity in NSSI Adolescents
NCT05968313Nonsuicidal Self Injury, Pain Empathy
University of Electronic Science and Technology of China
Observational
80
Chengdu
2023-12-06
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang
2023-12-04
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xi’an, Chengdu
2023-12-01
Not yet open
Shuangyue Liu
Phase 2
178
Chengdu
2023-12-01
Active, closed
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Ha’erbin, Jinan
2023-12-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Recruiting
West China Hospital
Phase 2
17
Chengdu
2023-11-30
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Recruiting
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Recruiting
West China Second University Hospital
Observational
22
Chengdu
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Active, closed
West China Hospital
Phase 1/2
9
Chengdu
2023-11-20
Recruiting
West China Hospital
Early Phase 1
12
Chengdu
2023-11-17
Active, closed
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
NCT05808608Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
DrugsAxitinib·Cadonilimab
Hao Zeng
Phase 1/2
37
Chengdu
2023-11-17
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
480
Beijing, Changsha, Chengdu, Haerbin, Huizhou, Kaifeng, Luoyang, Luzhou
2023-11-16
Recruiting
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Active, closed
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Active, closed
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Active, closed
AstraZeneca
Phase 3
1,835
Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou
2023-11-07
By invitation
West China Second University Hospital
Observational
100
Chengdu
2023-11-01
Recruiting
Assessment System of Sarcopenia in Lung Cancer Patients
NCT06327594Sarcopenia, Lung Cancer, Ultrasound
West China Hospital
Observational
1,500
Chengdu
2023-11-01
Recruiting
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Active, closed
AstraZeneca
Phase 3
895
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-10-24
Recruiting
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
82
Shanghai, Chengdu, Ha’erbin, Wuhan
2023-10-17
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Beijing, Bengbu, Chengde, Chengdu, Jiaxing, Jinan, Nanchang, Nanyang
2023-10-12
Recruiting
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Active, closed
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
56
Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou
2023-09-28
Recruiting
AstraZeneca
Phase 3
800
Beijing, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou
2023-09-22
Recruiting
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Recruiting
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
NCT06228677Resistant Hypertension, Secondary Hypertension, Secondary Hypertension to Endocrine Disorders, Primary Aldosteronism
First Affiliated Hospital of Chengdu Medical College
Observational
196
Chengdu
2023-09-18
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangdong Province Guangzhou City, Guangzhou
2023-09-18
Recruiting
RemeGen Co., Ltd.
Phase 1/2
221
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2023-09-14
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai
2023-09-13
By invitation
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Recruiting
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Phase 3
1,920
Chengdu
2023-09-08
Recruiting
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Recruiting
Gilead Sciences
Phase 3
402
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei
2023-09-07
By invitation
West China Second University Hospital
Observational
500
Chengdu
2023-09-01
Recruiting
Physiological Studies in the Prone Position in Patients With ARDS
NCT06586736Acute Respiratory Distress Syndrome, Mechanical Ventilation, Prone Positioning
West China Hospital
Observational
100
Chengdu
2023-09-01
Not yet open
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
NCT05730595Colorectal Neoplasms, Fluorescence, Lymph Node Excision
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
550
Hefei, Beijing, Chengdu, Fuzhou, Guangzhou, Shijiazhuang, Haerbin, Nanjing
2023-09-01
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Active, closed
Hoffmann-La Roche
Observational
1,000
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot
2023-08-25
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu
2023-08-22
Recruiting
AstraZeneca
Observational
52,121
Beijing, Changsha, Chengdu, Guangzhou, Wuhan
2023-08-21
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Nanchang, Neijiang
2023-08-18
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
Sinocelltech Ltd.
Phase 3
18,000
Nanning, Zhengzhou, Taiyuan, Chengdu, Kunming
2023-08-13
Active, closed
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Active, closed
GeneCradle Inc
Phase 1/2
33
Beijing, Chengdu, Chongqing, Wuhan
2023-08-01
Recruiting
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Not yet open
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
89
Beijing, Chengdu, Hangzhou, Shanghai
2023-07-30
Active, closed
Belite Bio, Inc
Phase 3
429
Beijing, Chengdu, Guandong, Zhejiang
2023-07-27
Recruiting
Sichuan Cancer Hospital and Research Institute
Phase 3
286
Chengdu
2023-07-24
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Guangzhou, Chengdu, Beijing
2023-07-11
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
80
Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang
2023-07-06
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Rows per page Showing 501–1000 of 1307
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,307 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

746 of the 1,307 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 170 have not yet opened recruitment, 364 are active but closed to new participants, and 27 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.